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Shiga toxins (Stxs) induce apoptosis via activation of the intrinsic and extrinsic pathways in many cell types.
Toxin-mediated activation of the endoplasmic reticulum (ER) stress response was shown to be instrumental in
initiating apoptosis in THP-1 myeloid leukemia cells. THP-1 cells responded to Shiga toxin type 1 (Stx1) in a
cell maturation-dependent manner, undergoing rapid apoptosis in the undifferentiated state but reduced and
delayed apoptosis in differentiated cells. The onset of apoptosis was associated with calpain activation and
changes in expression of C/EBP homologous protein (CHOP), Bcl-2 family members, and death receptor 5
(DR5). Ligation of DR5 by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates
the extrinsic pathway of apoptosis. We show here that expression of TRAIL and DR5 is increased by Stx1
treatment. Addition of exogenous TRAIL enhances, and anti-TRAIL antibodies inhibit, Stx1-induced apoptosis
of THP-1 cells. Silencing of CHOP or DR5 expression selectively prevented caspase activation, loss of mito-
chondrial membrane potential, and Stx1-induced apoptosis of macrophage-like THP-1 cells. In contrast, the
rapid kinetics of apoptosis induction in monocytic THP-1 cells correlated with rates of calpain cleavage. The
results suggest that CHOP-DR5 signaling and calpain activation differentially contribute to cell maturation-
dependent Stx1-induced apoptosis. Inhibition of these signaling pathways may protect cells from Stx cytotoxicity.
Shiga toxins (Stxs) are major virulence factors expressed by
the enteric pathogens Shigella dysenteriae serotype 1 and cer-
tain Escherichia coli serotypes referred to as Shiga toxin-pro-
ducing E. coli (STEC). Infections with Stx-producing bacteria
are associated with watery diarrhea that may progress to
bloody diarrhea, acute renal failure, and central nervous sys-
tem complications such as lethargy, seizures, and paralysis
(60). STEC is a particular public health concern in developed
nations, with approximately 73,000 cases annually of hemor-
rhagic colitis caused by E. coli O157:H7 and 37,000 annual
cases caused by STEC non-O157 serotypes in the United
States (42). The histopathological hallmark of disease caused
by Stxs is damage to endothelial cells lining colonic capillaries,
renal glomeruli and arterioles, and central nervous system
(CNS) blood vessels (46). The essential role of Stxs in patho-
genesis has been confirmed using animal models in which the
infusion of the toxins causes extensive microvascular thrombo-
ses in the kidney and CNS and, in some cases, ataxia and limb
paralysis (43, 61). S. dysenteriae serotype 1 produces Shiga
toxin, while STEC may express one or more toxin variants
categorized as Shiga toxin type 1 (Stx1) or Shiga toxin type 2
(Stx2) based on their antigenic similarity to Shiga toxin (56).
All Stxs possess an AB5 structure composed of a monomeric A
subunit in noncovalent association with a pentamer of B sub-
units (17). The B subunits mediate toxin binding by interaction
with the membrane neutral glycolipid globotriaosylceramide
(Gb3) (38). The toxins are then internalized and undergo a
complex series of intracellular routing events, collectively
termed retrograde transport, which ultimately deliver the tox-
ins to the endoplasmic reticulum (ER) lumen (50). In the ER,
the A subunit is proteolytically processed, and a fragment of
the A subunit retrotranslocates into the cytosol. The N-glyco-
sidase activity associated with the processed A subunit cata-
lyzes the inactivation of eukaryotic ribosomes and inhibits pro-
tein synthesis (12, 51).
In addition to the capacity to inhibit protein synthesis, Stxs
have been shown to induce apoptosis, or programmed cell
death, in many cell types (5). The toxins appear to activate
apoptotic signaling through an extrinsic (death receptor-medi-
ated signaling) or an intrinsic (mitochondrion-mediated signal-
ing) pathway. For example, the toxins have been shown to be
capable of directly activating initiator and executioner caspase
cascades but also to generate truncated BID (tBID) which
translocates to mitochondrial membranes, leading to increased
mitochondrial membrane permeability, release of cytochrome
c, and formation of the apoptosome (6, 18, 34). As a result of
signaling through the intrinsic or extrinsic pathway, intoxicated
cells display characteristics of apoptosis such as DNA fragmen-
tation, cell shrinkage, membrane blebbing, and chromatin con-
densation.
We previously showed that Stx1 induced apoptosis in the
human myelogenous leukemia cell line THP-1 in a cell mat-
uration-dependent manner. Undifferentiated, nonadherent
monocytic THP-1 cells underwent rapid apoptosis when
treated with Stx1, while differentiation to the adherent, mac-
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rophage-like state was associated with increased resistance
to the cytotoxic action of the toxins, with only approximately
30% of cells undergoing delayed apoptosis (22). The induc-
tion of apoptosis by Stx1 involved the activation of the ER
stress response in both monocytic and macrophage-like THP-1
cells (33, 36). Stx1 induced the expression of the ER stress
effectors C/EBP homologous protein (CHOP), tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL), and
death receptor 5 (DR5) in monocytic THP-1 cells. Delivery of
functional Stx1 into the cytosol of monocytic THP-1 cells led to
downregulated expression of the prosurvival factor Bcl-2, while
the delayed-apoptosis phenotype in macrophage-like cells was
associated with increased Bcl-2 expression, phosphorylation,
and mitochondrial translocation.
Increased expression of the apoptosis-inducing factor
TRAIL and its death-inducing receptor, DR5, enhances cell
death signals triggered during a prolonged ER stress response
(23, 68). TRAIL may be membrane associated or may be
cleaved from the cell surface by proteases to generate a soluble
ligand (26, 40). Engagement of TRAIL with its cognate recep-
tor DR5 activates the extrinsic pathway of apoptosis through
DR5 aggregation, the recruitment of the Fas-associated death
domain (FADD), and the formation of the death-inducing
signaling complex (DISC) (31, 53). The observation that ex-
pression of TRAIL and DR5 was upregulated by Stx1 treat-
ment of monocytic THP-1 cells suggested that this receptor-
ligand pair may contribute to rapid apoptosis induced by the
toxin in these cells. However, we also showed that calpains
were rapidly activated by Stx1 in monocytic THP-1 cells, and
calpains may directly cleave caspase-3 (36). The studies re-
ported here were designed to characterize the roles of TRAIL/
DR5 and calpains in the rapid apoptosis response of monocytic
cells and in delayed apoptosis in macrophage-like cells. We
show that Stx1-induced apoptotic signaling is amplified by the
addition of soluble TRAIL (sTRAIL) and inhibited by expo-
sure of cells to neutralizing anti-TRAIL antibodies prior to
intoxication. A reduction in CHOP or DR5 expression using
RNA interference (RNAi) techniques markedly protected
cells from apoptosis induced by Stx1, linking activation of the
ER stress response with apoptosis in this system. Signaling
through CHOP and DR5 led to activation of the initiator
caspase, caspase-8, and the executioner caspase, caspase-3, in
macrophage-like THP-1 cells, but the effect of CHOP and
DR5 knockdown on caspase activation and apoptosis of mono-
cytic cells was minimal. In contrast, the rate of calpain activa-
tion (cleavage) was directly correlated with the rapid onset of
apoptosis in monocytic THP-1 cells.
MATERIALS AND METHODS
Antibodies. Anti-human calpain-1/2 antibody was purchased from Calbio-
chem, San Diego, CA. Antibodies directed against human DR5, caspase-8,
caspase-3, and pan-actin were obtained from Cell Signaling Technologies, Bev-
erly, MA. Rabbit polyclonal purified human anti-CHOP was purchased from
Biolegend, San Diego, CA.
Cell culture. The human myelogenous leukemia cell line THP-1 (American
Type Culture Collection, Manassas, VA) was cultured in RPMI 1640 medium
(Gibco-BRL, Grand Island, NY) containing 10% fetal bovine serum (HyClone
Laboratories, Logan, UT), penicillin (100 U/ml), and streptomycin (100 g/ml)
at 37°C in 5% CO2 in a humidified incubator. Cells maintained under these
conditions were considered undifferentiated, monocytic cells. Monocytic cells
(1  106 cells/ml) were differentiated to the adherent macrophage-like state with
phorbol 12-myristate 13-acetate (PMA) (Sigma Chemical Co., St. Louis, MO) at
a concentration of 50 ng/ml for 48 h. Plastic-adherent cells were washed three
times with cold, sterile Dulbecco’s phosphate-buffered saline (PBS) (Sigma) and
then incubated with fresh medium lacking PMA but containing 10% fetal bovine
serum, penicillin (100 U/ml), and streptomycin (100 g/ml). The medium was
changed every 24 h for the next 3 days. Experiments were performed on the
fourth day after PMA removal.
Toxin purification. Stx1 purification was described previously (36). Briefly,
Stx1 was expressed from Escherichia coli DH5(pCKS112), a recombinant strain
harboring a plasmid carrying the stx1 operon under the control of a thermoin-
ducible promoter (62). Cells were lysed, and periplasmic extracts were subjected
to sequential ion-exchange and chromatofocusing chromatographies. The purity
of toxins was assessed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and Western blot analysis using anti-Stx1 specific anti-
bodies. Prior to use, Stx1 preparations were shown to contain 0.1 ng of endo-
toxin/ml by use of the Limulus amoebocyte lysate assay (Associates of Cape Cod,
East Falmouth, MA). Purified Stx1A, a holotoxin with two point mutations
(E167Q and R170L), was a kind gift from Shinji Yamasaki, Osaka Prefecture
University, Osaka, Japan. The site-directed mutations in the Stx1 A subunit
reduce toxin N-glycosidase activity by 5 log units (44). Purified Stx1 B subunits
were a kind gift from Cheleste Thorpe, Tufts University School of Medicine,
Boston, MA.
MTS-based cell cytotoxicity assay. Monocytic and macrophage-like THP-1
cells (5  104 cells per well) were seeded in 96-well microtiter plates prior to
treatment with Stx1 (400 ng/ml) or Stx1A (400 ng/ml). In some experiments,
neutralizing anti-tumor necrosis factor-related apoptosis-inducing ligand (anti-
TRAIL) antibodies (10 to 50 ng/ml; R&D Systems, Minneapolis, MN) were
added to the cells for 40 min prior to stimulation with Stx1 and incubation at
37°C in humidified 5% CO2. In some experiments, cells were treated with Stx1
or Stx1A for 24 h in RPMI 1640 medium containing 0.5% fetal bovine serum
(FBS) in the presence or absence of recombinant soluble TRAIL (sTRAIL) (10
to 50 ng/ml; R&D Systems, Minneapolis, MN). Control experiments with mono-
cytic and macrophage-like THP-1 cells treated with sTRAIL or anti-TRAIL
antibodies alone were included with each experiment. Cytotoxicity was determined
by a colorimetric assay (8) using the novel tetrazolium compound 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium in-
ert salt (MTS) (Promega, Madison, WI). MTS (50 l/5000 cells) was added to
each well and incubation continued for 2 h at 37°C in 5% CO2. The optical
density at 490 nm (OD490) was recorded with an automated microtiter plate
reader (Dynatech MR5000; Molecular Dynamics, Chantilly, VA). The percent-
age of cell death was determined using the following equation: percentage of cell
death  [(average OD490 of treated cells  average OD490 of control cells)/
average OD490 of control cells]  100. The background absorbance at 630 nm
measured with untreated cells was subtracted from each sample reading. The
reference wavelength of 630 nm was used to subtract background contributed by
excess cell debris and other nonspecific absorbance.
Human TRAIL immunoassay. Quantitation of human TRAIL/TNFSF10 pro-
tein was carried out using Quantikine colorimetric enzyme-linked immunosor-
bent assay (ELISA) kits (R&D Systems, Minneapolis, MN). Briefly, differenti-
ated THP-1 cells (5 106 cells/well) were stimulated with Stx1 (0 to 1,200 ng/ml)
for 24 h. Cell-free supernatants and cell lysates were prepared, and kit-specified
volumes of the samples were added in triplicate to 96-well polystyrene microtiter
plates coated with a mouse monoclonal antibody against TRAIL. Human
TRAIL immunoassay was performed according to the manufacturer’s instruc-
tions. Amounts of human TRAIL in cell-free supernatants or cell lysates were
estimated based on standard curves generated by serial dilutions of recombinant
human TRAIL.
Analysis of apoptosis by annexin V and propidium iodide staining. Monocytic
THP-1 cells were incubated with soluble TRAIL (50 ng/ml) or neutralizing
anti-TRAIL antibodies (50 ng/ml) for 30 min before treatment with Stx1 (400
ng/ml), Stx1A (400 ng/ml), or cycloheximide (CHX) (100 M) for various
times. Following treatment, cells were centrifuged at 200  g for 5 min, washed
in ice-cold sterile PBS, and stained using the annexin V-Fluos staining kit (Roche
Diagnostics, Indianapolis, IN). Cells were incubated in the provided incubation
buffer containing annexin V (AV) and propidium iodide (PI) for 20 min at room
temperature. After washing with PBS, apoptosis was measured by flow cytometry
(Becton-Dickinson, Palo Alto, CA). Fluorescence parameters were gated using
unstained and single-stained, untreated cells. At least 104 events were measured
for each sample. Total percent apoptosis was expressed as follows: percentage of
AV-positive (AV) cells  percentage of AV PI cells  background fluores-
cence.
Measurement of m. Loss of mitochondrial membrane potential (	
m) was
measured as described previously (35). Briefly, differentiated THP-1 cells (5 
106 cells/well) were transfected with DR5 small interfering RNA (siDR5) or
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CHOP siRNA (siCHOP) for 72 h, followed by treatment with Stx1 for 24 h. After
stimulation, cells were detached by treatment with Accutase (Innovative Cell
Technologies Inc., San Diego, CA) for 10 min. After centrifugation at 260 g for
5 min, supernatants were removed, and cells were washed in ice-cold PBS and
resuspended in 0.5 ml JC-1 assay buffer containing the reagent 5,5,6,6-tetrachloro-
1,1,3,3-tetraethylbenz-imidazolocarbocyanine iodine (JC-1). Cells were incubated
for 15 min at 37°C in the presence of 5% CO2, centrifuged at 400 g for 5 min, and
washed twice in JC-1 assay buffer. JC-1 fluorescence associated with mitochondrial
membranes was detected using flow cytometry.
Preparation of cellular lysates and Western blotting. Eighteen hours prior to
stimulation, differentiated THP-1 cells (5  106 cells/well) were washed twice in
cold Dulbecco’s PBS and RPMI 1640 containing 0.5% FBS. Cells were stimu-
lated with Stx1 (400 ng/ml), Stx1A (400 ng/ml), Stx1 B subunit (800 ng/ml), or
thapsigargin (Tg) (10 m) for 0 to 24 h. Cells were harvested and lysed with
modified radioimmunoprecipitation assay (RIPA) buffer as previously described
(16). For detection of CHOP, cells were lysed with modified lysis buffer (137 mM
NaCl, 15 mM EGTA, 0.1 mM sodium orthovanadate, 15 mM MgCl2, 0.1%
Triton X-100, 25 mM morpholinepropanesulfonic acid [MOPS] [pH 7.2], 100
mM phenylmethylsulfonyl fluoride [PMSF], and 20 M leupeptin). Extracts were
collected and cleared by centrifugation at 15,000 g for 10 min. Cell lysates from
monocytic THP-1 cells were prepared as previously described (33). Protein
concentrations in each extract were determined using the Micro bicinchoninic
acid (BCA) protein assay kit (Pierce, Rockford, IL). Equal amounts of proteins
(70 to 100 g/lane) were separated by 8% or 12% Tris-glycine SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were blocked with 5%
nonfat milk prepared with TBST (20 mM Tris [pH 7.6], 137 mM NaCl, 0.1%
Tween 20). Membranes were incubated with primary antibodies at 4°C for 24 h.
After washing, the membranes were incubated with horseradish peroxidase-
labeled secondary antibodies for 2 h at room temperature. Bands were visualized
using the Western Lightning chemiluminescence system (NEN-Perkins-Elmer,
Boston, MA). Data shown are from at least three independent experiments.
Relative protein expression levels were measured using NIH image J software.
Analysis of apoptosis by TUNEL staining. Apoptosis of adherent, macro-
phage-like THP-1 cells was determined using the in situ cell death detection kit
(Roche). Briefly, THP-1 cells (2  105 cells/well) were differentiated on eight-
well Lab-Tek chamber slides (Nalge-Nunc International, Naperville, IL), result-
ing in approximately 1  105 viable cells/well. Cells were treated with Stx1 in the
presence or absence of sTRAIL or anti-TRAIL antibodies for 24 h. Cells were
then fixed in freshly prepared 4% paraformaldehyde for 1 h, rinsed with PBS,
and treated with permeabilization solution for 2 min on ice. Following washing,
terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) reaction mix was added and left for 1 h at 37°C in the dark. Cells were
washed with PBS, and fluorescent nuclei detected were quantified with a Bio-Tek
(Richmond, VA) Synergy HT microplate reader. In order to count TUNEL-
positive cells in the siRNA-transfected cells, the total number of TUNEL-posi-
tive cells was determined from 10 different fields (magnification, 20) for each
treatment from three independent experiments. In parallel, total numbers of
cells were determined by counting 4,6-diamidino-2-phenylindole (DAPI) (In-
vitrogen, Eugene, OR)-stained nuclei for each treatment. Percentages of
TUNEL-positive cells above untreated controls were calculated as follows: per-
cent apoptosis  (number of TUNEL-positive cells/number of DAPI-positive
total cells)  100.
siRNA transfection. Differentiated or undifferentiated THP-1 cells were trans-
fected with 100 to 200 pmol ON-TARGETplus SMARTpool DR5 siRNA,
CHOP siRNA, or nontargeting (NT) negative-control siRNA (Dharmacon, Inc.,
Chicago, IL) using transIT-TKO transfection reagent (Mirus Bio Corporation,
Madison, WI) as per the manufacturer’s instructions. Briefly, DR5, CHOP, or
nontargeting siRNA was added to transfection reagent diluted in serum-free
medium and incubated for 15 min to allow the formation of transfection com-
plexes prior to transfection. The siRNA complexes were added to 1  106 to 2 
106 cells/well grown in 6- or 12-well plates and incubated for 48 h, followed by
the addition of fresh serum-containing medium to each well. Transfection
efficiency was measured by observing Cy3-labeled fluorescence of the control
siRNA (New England BioLabs, Ipswich, MA) with a fluorescence-activated
cell sorter (FACSCalibur; Becton-Dickinson, Palo Alto, CA). Using this
protocol, typical transfection efficiencies were 70 to 80%. After the trans-
fected cells were incubated with Stx1 (400 ng/ml) for 0, 8, or 24 h, Western
blotting was performed with specific antibodies against human DR5, CHOP,
or caspase-3 and -8. In order to address the influence of silencing CHOP or
DR5 on apoptosis, the TUNEL assay was carried out following exposure of
cells to Stx1.
Statistics. Data are reported as means  standard errors of the mean (SEM)
for at least three independent experiments. Statistical analyses of data were
performed with EXCEL (Microsoft, Redmond, WA). The Student t test was
used to measure differences in samples. Depending on the assay, a P value of
0.05, 0.01, or 0.001 was considered significant.
RESULTS
TRAIL contributes to Stx1-mediated apoptosis of monocytic
THP-1 cells. We have previously shown that Stx1 induces
apoptosis of the myelogenous leukemia cell line THP-1
through activation of the ER stress response (36). Sensitivity to
cell killing and the onset of apoptosis were cell maturation
dependent; that is, replicating, nonadherent monocyte-like
THP-1 cells were highly toxin sensitive and underwent rapid
apoptosis, while differentiated, adherent macrophage-like
THP-1 cells were relatively less toxin sensitive and the subset
of cells that died in response to toxin treatment displayed a
delayed onset of apoptosis (22, 35). Toxin activation of the ER
stress response increased the expression of TRAIL and DR5 in
toxin-sensitive monocytic cells (36), suggesting that TRAIL-
DR5 ligation may contribute to the toxin-sensitive phenotype
of undifferentiated cells. Annexin V (AV) binding to phospha-
tidylserine in the outer plasma membrane is a reliable early
marker of apoptosis, while late-stage apoptosis includes the
loss of plasma membrane integrity and uptake of propidium
iodide (PI) (14). To explore the role of TRAIL-DR5 ligation in
the rapid killing of monocytic THP-1 cells, we measured apop-
tosis by flow cytometry following exposure to Stx1 with or
without the addition of exogenous soluble TRAIL (sTRAIL)
or anti-TRAIL antibodies with subsequent staining with AV
and PI over a 4- to 6-h time course.
Characteristic fluorescence-activated cell sorter (FACS)
scatter plots of monocytic cells treated with Stx1 with or with-
out sTRAIL for 4 h are shown in Fig. 1A. Additive percentages
of cells staining AV (right lower quadrant) and AV PI
cells (right upper quadrant) were calculated from three inde-
pendent experiments to show the kinetics of apoptosis induc-
tion (Fig. 1B) using cells treated with Stx1, Stx1 plus sTRAIL,
or Stx1 plus anti-TRAIL antibodies for 4 to 6 h. The addition
of sTRAIL to Stx1-treated cells increased apoptosis. While
significant protection was achieved at 4 h, the percentage of
apoptosis at 5 to 6 h was lower in the presence of anti-TRAIL
antibodies, although the differences at these times did not
achieve statistical significance. Figure 1C shows the results of
three independent FACS experiments to examine the role of
anti-TRAIL antibodies in blocking Stx1-induced apoptosis.
Untreated monocytic THP-1 cells displayed low levels (7.1%)
of spontaneous apoptosis, and cells treated with sTRAIL alone
(50 ng/ml) displayed modest increases (13.1%) in apoptosis
which were eliminated by anti-TRAIL antibody treatment.
Treatment of monocytic cells with Stx1 alone for 4 h resulted
in approximately 37% of cells staining AV plus AV PI. We
noted a dose-dependent increase in apoptosis mediated by the
addition of sTRAIL to Stx1-treated cells (10 to 50 ng/ml
sTRAIL) (data not shown). The addition of sTRAIL (50 ng/
ml) to Stx1-treated cells increased the percentage of apoptotic
cells to 54%. Stx1-mediated monocytic cell apoptosis was sig-
nificantly (P  0.005) reduced to 24.6% by the addition of
anti-TRAIL antibody. Interestingly, while anti-TRAIL anti-
body pretreatment protected cells from apoptosis induced by
sTRAIL or Stx1 alone, antibody pretreatment failed to signif-
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icantly protect cells from apoptosis induced by Stx1 plus
sTRAIL.
To assess the role of Stx1 enzymatic activity in apoptosis
induction, monocytic THP-1 cells were treated with a purified
Stx1 holotoxin molecule (Stx1A) containing two point muta-
tions which drastically reduce enzymatic activity (44). All of the
treatment regimens using Stx1A failed to induce apoptosis
above spontaneous levels (Fig. 1C), confirming the necessity
for toxin enzymatic activity in apoptosis induction. However,
we also treated monocytic THP-1 cells with cycloheximide
(CHX), which we have shown to be an effective inhibitor of
protein synthesis in monocytic THP-1 cells (34), yet CHX
failed to trigger apoptosis (Fig. 1C). We previously showed
that Stx1 treatment of monocytic THP-1 cells robustly in-
creased DR5 expression at transcriptional and translational
levels (36). However, treatment of cells with CHX for 0 to 12 h
did not activate DR5 expression (data not shown). Thus, pro-
tein synthesis inhibition per se does not appear to be required
for apoptosis induction or activation of the ER stress response.
Stx1 induces the expression of TRAIL and DR5 by macro-
phage-like THP-1 cells. The capacity of Stx1 to induce TRAIL
and DR5 expression by macrophage-like THP-1 cells has not
been characterized. We used ELISAs to measure the produc-
tion of both soluble and cell-associated TRAIL by macro-
phage-like cells following treatment with increasing amounts
of Stx1 for 24 h (Fig. 2A). We noted a toxin dose-dependent
increase in soluble and cell-associated TRAIL, consistent with
earlier studies using Stx1-treated monocytic THP-1 cells. Using
reverse transcription-PCR (RT-PCR) (Fig. 2B), we detected
elevated levels of DR5 mRNA as early as 2 h after toxin
treatment. Elevated levels of transcripts were maintained up to
4 h but then declined at 6 h after toxin treatment. Treatment of
cells with Stx1A for 4 h failed to induce DR5 mRNA expres-
sion. DR5 protein production was monitored by Western blot-
ting of cell lysates prepared from macrophage-like cells treated
with Stx1, Stx1A, or purified Stx1 B subunits. As shown in Fig.
2C, elevated levels of DR5 protein were detected beginning at
4 h and peaking at 8 to 16 h after Stx1 treatment. The ER stress
inducer thapsigargin (Tg) strongly stimulated DR5 protein ex-
pression. Neither Stx1A nor Stx1 B subunits were capable of
inducing DR5 synthesis above basal levels. Thus, the treatment
of both monocytic (36) and macrophage-like THP-1 cells in-
duces TRAIL and DR5 expression.
Additive cytotoxic effect of TRAIL and protective effect of
neutralizing anti-TRAIL antibody on Stx1-mediated cytotox-
icity. TRAIL binds to death domain-containing receptors DR4
FIG. 1. Effects of Stx1, sTRAIL, and anti-TRAIL antibody on apoptosis of undifferentiated (monocytic) THP-1 cells. (A) Representative FACS
scatter plots of untreated monocytic THP-1 cells and cells treated with soluble TRAIL, Stx1, or Stx1 plus TRAIL for 4 h, showing percentages of
cells staining annexin V positive (lower right quadrants) or annexin V/propidium iodide (PI) double positive (upper right quadrants). (B) Mono-
cytic THP-1 cells were either untreated or incubated with Stx1 with or without soluble TRAIL or neutralizing anti-TRAIL antibodies for 4 to 6 h.
At each time point, cells were stained with annexin V and PI and analyzed by flow cytometry for apoptosis. The data shown are the means  SEM
of additive percentages of AV plus AV PI cells for three independent experiments. *, significant difference (P  0.05) between cells treated
with Stx1 versus Stx1 plus TRAIL for 4 h; **, significant difference (P  0.01) between cells treated with Stx1 versus Stx1 plus anti-TRAIL
antibodies for 4 h. (C) Monocytic THP-1 cells were incubated with Stx1 or Stx1A for 4 h with or without treatment with soluble TRAIL (sTR)
or neutralizing anti-sTRAIL antibodies (anti-sTR). Cells were stained with annexin V and PI, and the effects of treatment combinations on
apoptosis were measured by flow cytometry. Results represent means  SEM for three independent experiments. *, significant difference (P 
0.001) between treated cells and untreated cells; **, significant difference (P  0.005) between cells treated with Stx1 plus sTR versus Stx1 plus
anti-sTR; #, significant difference (P  0.05) between cells treated with Stx1 versus Stx1 plus sTR; ##, significant difference (P  0.01) between
cells treated with Stx1 versus Stx1 plus anti-sTR. Cycloheximide (CHX) served as a negative control.
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and DR5, leading to recruitment of the death-inducing signal-
ing complex and caspase-8-initiated apoptotic signaling (31,
55). We demonstrated using undifferentiated monocytic
THP-1 cells that Stx1 rapidly activated the ER stress response,
resulting in procaspase-8 cleavage and elevated levels of
sTRAIL and DR5 expression (36). Given our finding that Stx1
treatment of macrophage-like THP-1 cells also induces TRAIL
and DR5 expression, we determined if the addition of exoge-
nous sTRAIL in the presence of Stx1 influenced cell death.
Differentiated THP-1 cells either were treated with Stx1 for
24 h and posttreated 40 min later with sTRAIL or were pre-
treated with neutralizing anti-TRAIL antibodies for 40 min
prior to Stx1 treatment to measure protection from Stx1-in-
duced cell death using the indicator dye MTS. The percentage
of cell death was normalized to control (untreated) cells. The
addition of sTRAIL to Stx1-treated THP-1 cells showed a
dose-dependent increase in percentages of cell death com-
pared to that for cells treated with Stx1 alone (Fig. 3A). Max-
imal cell death occurred when cells were treated with Stx1 plus
50 ng/ml sTRAIL. Anti-TRAIL antibody partially protected
macrophage-like THP-1 cells from Stx1- and Stx1-plus-
sTRAIL-induced apoptosis in a dose-dependent manner (Fig.
3A). We next performed comparative analyses to evaluate
cytotoxicity in response to sTRAIL (50 ng/ml) or neutralizing
anti-TRAIL (50 ng/ml) in Stx1- or Stx1A -treated monocytic
and macrophage-like THP-1 cells at 0, 6, and 24 h. In accor-
dance with our earlier studies, monocytic THP-1 cells were
more sensitive to Stx1 (Fig. 3B). By 24 h, monocytic cells
treated with Stx1 plus sTRAIL showed 85% cytotoxicity,
while macrophage-like cells treated with the same agents
showed only 51% of cell death, a percentage of cell death that
is only 4% increased compared to that at the 6-h time point
(Fig. 3B). These data suggest not only that monocytic cells are
more sensitive to cell death induced by Stx1 and TRAIL than
are macrophage-like cells but that only a subset of differenti-
ated cells are susceptible to apoptosis induction by Stx1 plus
sTRAIL.
TRAIL and DR5 contribute to apoptosis induction in Stx1-
treated macrophage-like THP-1 cells. We used TUNEL stain-
ing to examine the sensitivity of adherent, macrophage-like
THP-1 cells to apoptosis induced by Stx1 with or without
sTRAIL or anti-TRAIL antibodies. Characteristic fluorescent
micrographs are shown in Fig. 4A, while the statistical analyses
of measurements of TUNEL fluorescence intensities from
FIG. 2. Stx1 induces TRAIL and DR5 expression by macrophage-like THP-1 cells. (A) Macrophage-like THP-1 cells were treated with the
indicated amounts of Stx1 for 24 h. Cell-free supernatants and cellular lysates were collected and analyzed by ELISA specific for human TRAIL
production. C, control (untreated) cells. The data shown are means  SEM from at least three independent experiments. *, significant difference
(P  0.05) between Stx1-treated cells and control cells. (B) Analysis of DR5 mRNA expression by RT-PCR using total RNA extracted from
macrophage-like THP-1 cells treated with Stx1 for 0 to 24 h (upper panel), or Stx1 or Stx1A for 4 h (lower panel). Primers for amplification of
-actin were used as a control. The data shown are characteristic of three independent experiments. (C) Analysis of DR5 protein expression by
Western blotting (WB) using cell lysates prepared from macrophage-like THP-1 cells treated with Stx1 or thapsigargin (Tg) for 0 to 16 h, with
Stx1A or Stx1 B subunits for 0 to 16 h, or with Tg for 4 h. Antibodies directed against -actin were used as a loading control. The data shown
are characteristic of three independent experiments.
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three independent experiments are shown in Fig. 4B. Un-
treated cells and cells treated with sTRAIL, anti-TRAIL anti-
bodies, or sTRAIL plus anti-TRAIL antibodies for 24 h
showed few fluorescent nuclei characteristic of apoptotic cells.
Macrophage-like cells treated with Stx1 displayed significantly
(P 0.001) increased fluorescence intensity, which was further
increased by the addition of sTRAIL (50 ng/ml). Treatment of
cells with Stx1 plus anti-TRAIL significantly (P  0.01) re-
duced TUNEL fluorescence. Use of the Stx1A holotoxin
showed that toxin enzymatic activity was essential for apoptosis
induction. The ER stress inducer thapsigargin significantly in-
creased TUNEL fluorescence. The TUNEL assay is likely to
dramatically underestimate the degree of cell death induced by
Stx1 and Stx1 plus sTRAIL, since it detects fluorescence of
adherent cells. We showed that approximately 60% of macro-
phage-like THP-1 cells detach from the wells following treat-
ment with Stx1 or Stx1 plus sTRAIL for 24 h (Fig. 4C). How-
ever, pretreatment of toxin-treated cells with anti-TRAIL
antibodies reduced cell detachment by approximately 20%.
Taken together, these data suggest that, just as was the case
with monocytic THP-1 cells, Stx1-induced expression of
TRAIL may contribute, in part, to apoptosis of macrophage-
like THP-1 cells, albeit with different kinetics.
Silencing of DR5 or CHOP protects macrophage-like, but
not monocytic, THP-1 cells from Stx1-induced apoptosis.
Since activation of the ER stress response leading to increased
TRAIL and DR5 expression appears to contribute to Stx1-
induced apoptosis and since apoptotic cell death induced by
Stx1 plus sTRAIL is greater than cell death induced by TRAIL
or Stx1 alone, we hypothesized that silencing of DR5 expres-
sion may protect cells from intoxication. By use of RNA inter-
ference (RNAi), an elegant strategy to achieve specific gene
silencing at the posttranscriptional level (25), DR5 expression
was inhibited and its knockdown verified by Western blotting
using DR5-specific antibodies with extracts prepared from
Stx1-treated macrophage-like THP-1 cells (Fig. 5A). Thapsi-
FIG. 3. Comparative cytotoxicities of undifferentiated and differentiated THP-1 cells treated with Stx1 or Stx1A with or without sTRAIL or
anti-TRAIL antibodies. (A) Macrophage-like THP-1 cells were treated with Stx1 alone or with various amounts of soluble TRAIL (TR) (10 to 50
ng/ml) for 40 min before Stx1 treatment or were treated with neutralizing anti-TRAIL antibodies (anti-TR) (10 to 50 ng/ml) for 40 min after Stx1
treatment. Cells were then incubated for 24 h, followed by measurement of cytotoxicity. The data shown are means  SEM from at least three
independent experiments. *, significant difference (P  0.05) between Stx1-treated cells and Stx1-plus-TR- or anti-TR-treated cells. (B) Undif-
ferentiated (monocytic) and differentiated (macrophage-like) THP-1 cells were seeded in 96-well microtiter plates. In some wells, cells were treated
with Stx1 or Stx1A for 6 or 24 h in the presence or absence of sTRAIL (TR) (50 ng/ml). In some wells, cells were treated with anti-TRAIL
antibodies (antiTR) (50 ng/ml) for 40 min prior to stimulation with Stx1 or Stx1A. Controls included untreated cells and cells treated with
sTRAIL or neutralizing anti-TRAIL antibodies only. Cytotoxicity was determined by colorimetric assay using MTS as described in Materials and
Methods. The percentage cell death was normalized to control (untreated) cells. Data shown are the means  SEM for at least three independent
experiments.
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FIG. 4. Effects of Stx1 and TRAIL on apoptosis in macrophage-like THP-1 cells. (A) Macrophage-like THP-1 cells were treated with Stx1,
Stx1A, sTRAIL (sTR) (50 ng/ml), or anti-TRAIL antibodies (antiTR) (50 ng/ml) for 24 h. Control, untreated cells. Cells were fixed, permeab-
ilized, and incubated with TUNEL reaction solution. Representative TUNEL-positive cells visualized by fluorescence microscopy are shown.
(B) The relative fluorescence intensity of each treatment was measured using a microplate reader. Results shown are the means  SEM from at
least three independent experiments. *, significant difference (P  0.001) between treated cells and control cells; **, significant difference (P 
0.01) between Stx1 plus sTR and Stx1 plus anti-TR antibodies. Thapsigargin was used as a positive control for ER stress-induced apoptosis. (C) To
determine the extent of cell detachment after various treatments, differentiated THP-1 cells were treated with Stx1, Stx1A, or thapsigargin for
24 h. In some experiments, cells were pre- or posttreated with sTRAIL or anti-TRAIL antibodies. Culture supernatants were removed, and 100-l
suspensions of trypsinized THP-1 cells were transferred to microcentrifuge tubes. Trypan blue exclusion was used to distinguish viable and
nonviable cells. Two hundred microliters of the trypan blue suspensions were transferred to hemocytometer chambers for counting. Viable cells
were counted and expressed as a percentage of untreated control cell numbers.
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FIG. 5. Silencing of DR5 and CHOP expression reduces CHOP-dependent expression of DR5- and Stx1-induced apoptosis in macrophage-like,
but not monocytic, THP-1 cells. (A and B) Differentiated THP-1 cells were transfected with or without 200 pmol siRNA duplexes targeting DR5
(siDR5) or CHOP (siCHOP) or with nontargeting siRNA duplexes (NTsiRNA) as described in Materials and Methods. After 72 h, cells were
exposed to Stx1 for 8 h, followed by Western blotting using anti-DR5 (A and B) and anti-CHOP (B) antibodies, which recognize 46-kDa (precursor
form)/41-kDa (mature form) and 29-kDa proteins, respectively. -Actin was used as an equal-protein-loading control. The bar graphs show the
quantitative analysis (means  SEM) of DR5 or CHOP protein expression from three independent experiments. *, significant difference in DR5
protein expression (P  0.01; Stx1 versus siRNA DR5 plus Stx1 treatment). (C) Effect of DR5 or CHOP knockdown on apoptosis of macrophage-
like THP-1 cells. Differentiated THP-1 cells were transfected with DR5 siRNA (siDR5), CHOP siRNA (siCHOP), or nontargeting siRNA
(NTsiRNA) or without siRNA (mock) for 72 h, followed by Stx1 treatment for another 24 h. Cells were fixed, permeabilized, and incubated with
TUNEL reaction solution or DAPI to stain nuclei. Cells were visualized by fluorescence microscopy, and 10 different fields (magnification, 20)
for each treatment were selected to count total numbers of TUNEL positive cells. Total numbers of cells per field (magnification, 20) were also
counted, and the percentage of apoptotic cells above that for untreated controls were calculated as described in Materials and Methods. Upper
panels, representative fields showing TUNEL-positive cells from each treatment. Lower bar graph, quantitative data showing percentage of
apoptosis (means  SEM from at least four independent experiments) for each treatment. *, significant difference (P  0.001) for cells treated
with Stx1 alone versus siDR5- plus Stx1-treated cells. (D) Monocytic THP-1 cells transfected with siRNAs specific for DR5 (siDR5), CHOP
(siCHOP), or nontargeting siRNA (NTsiRNA) or mock transfected were treated with Stx1 for 5 h. Expression of DR5 and CHOP was assessed
by Western blotting as outlined above. The bar graph depicts quantitative analysis (means SEM) of DR5 or CHOP protein expression from three
independent experiments. *, significant difference in DR5 and CHOP protein expression (P  0.01). (E) Quantitative data showing percentages
of apoptosis for each treatment from the FACS scatter plots of untreated monocytic THP-1 cells, cells treated with Stx1 alone, or cells treated with
siRNAs plus Stx1. Results are the means  SEM from at least four independent experiments.
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gargin (Tg), a well characterized inducer of the ER stress
response, was used as a positive control to evaluate DR5 RNAi
knockdown efficacy. Quantitative analysis showed that trans-
fection of Stx1- and Tg-treated cells with DR5 siRNA signifi-
cantly reduced (P  0.01; Stx1 versus siRNA DR5 plus Stx1)
DR5 protein expression (Fig. 5A, bar graph). Earlier studies
have shown that increased expression of the transcriptional
activator C/EBP homologous protein (CHOP) is required for
increased DR5 expression (57, 68), and we have shown that
Stx1-mediated activation of the ER stress response upregu-
lated CHOP expression (36). We reasoned, therefore, that
RNAi knockdown of the regulator CHOP would inhibit Stx1-
induced DR5 expression. CHOP expression was reduced by
62% in comparison to cells treated with Stx1 alone or Stx1 plus
nontargeting (NT) siRNA (Fig. 5B). As predicted, CHOP
knockdown negatively affected DR5 mRNA expression, man-
ifesting a 60% reduction in DR5 expression, while CHOP
transcript levels were not susceptible to DR5 knockdown in the
Stx1-treated macrophage-like cells (Fig. 5B, bar graph). These
data indicate that CHOP is an upstream regulator in the ER
stress pathway involved in DR5 expression.
To investigate the functional significance of RNAi silencing
of DR5 or CHOP expression, we explored effects on apoptosis
induction using TUNEL staining with Stx1-treated macro-
phage-like THP-1 cells transfected or not with DR5 or CHOP
siRNA (Fig. 5C). Examination of characteristic fluorescence
micrographs (Fig. 5C, upper panels) shows that fluorescence
intensities were reduced by DR5 and CHOP knockdown. Sta-
tistical analysis of four independent experiments using DR5 or
CHOP siRNA-transfected cells reveals that fluorescent signal
was significant reduced (P  0.001) compared to that in cells
treated with Stx1 alone (Fig. 5C, bar graph). In contrast, nei-
ther the nontargeting (NT) siRNA plus Stx1 nor mock trans-
fection treatment plus Stx1 significantly altered the percentage
of apoptotic cells compared to treatment with Stx1 alone. To
determine whether targeting of DR5 and CHOP is involved in
reduction of apoptosis in undifferentiated monocytic cells, cells
were transfected with DR5 or CHOP siRNA and then incu-
bated with Stx1 for 5 h, followed by annexin-PI apoptosis
analysis. Although siRNAs effectively reduced DR5 and
CHOP expression in monocytic THP-1 cells (Fig. 5D), unlike
in macrophage-like cells, silencing of DR5 and CHOP had
modest effects on cytotoxicity mediated by Stx1 treatment in
the monocytic THP-1 cells (Fig. 5E). Treatment of cells with
DR5 or CHOP siRNA alone did not cause a cytotoxic effect
above spontaneous control levels (data not shown). We con-
clude that the ablation of DR5 or CHOP expression protects
macrophage-like cells from Stx1-induced apoptosis. However,
the data also support the concept that signaling through DR5
may play a relatively less important role in apoptosis induction
in the highly toxin-sensitive monocytic THP-1 cells.
Signaling through CHOP-DR5 is involved in caspase-3 and
-8 activation in Stx1-treated macrophage-like cells but not
monocytic cells. The upregulation of DR5 and subsequent
binding of TRAIL may result in the formation of the death-
inducing signaling complex (DISC) involved in the activation
of the extrinsic and intrinsic pathways of apoptosis induction
(21, 39). Initiator caspases which associate with the DISC are
cleaved and, in turn, activate executioner caspases which then
activate proximal mediators of apoptosis or inhibit prosurvival
mediators, e.g., cleavage and activation of proapoptotic Bcl-2
family members, and cleavage and inactivation of DNA repair
enzymes (30, 32, 37, 63). In response to Stx1 treatment,
caspase-3 and -8 were the major caspases activated in both
undifferentiated and differentiated THP-1 cells, showing max-
imal activation at 8 h after toxin treatment (34, 35). To further
understand the requirements necessary to activate caspase-3
and -8, differentiated THP-1 cells were treated with Stx1,
Stx1A holotoxin, and Stx1 B subunits for 8 h. As shown in Fig.
6A, Stx1 treatment increased caspase-3 and -8 activation
(cleavage), while the activity was not detectable in Stx1A and
Stx1 B subunit-treated cells. Thus, as was the case with apop-
tosis induction, active Stx1 appeared to be necessary for
caspase activation. We reasoned that if Stx1-induced upregu-
lation of CHOP, DR5, and sTRAIL activates death receptor-
mediated apoptotic pathways, then DR5 DISC-associated
caspases should be activated. To evaluate this mechanism, both
differentiated and undifferentiated THP-1 cells were trans-
fected with siRNA duplexes to specifically silence DR5 and
CHOP expression. After intoxication, Western blotting was
carried out to measure caspase-3 and -8 activation. DR5 and
CHOP knockdown reduced levels of caspase-3 and -8 activa-
tion in differentiated THP-1 cells (Fig. 6B), although some
caspase activation was evident in siRNA-transfected lysates
(Fig. 6B, bar graph). In contrast, caspase activation was not
reduced following DR5 or CHOP knockdown in monocytic
THP-1 cells (Fig. 6C).
Signaling through the CHOP-DR5 pathway is involved in
activating the mitochondrion-mediated pathway of apoptosis.
We have shown that Stx1 induced THP-1 cell apoptosis by the
intrinsic (mitochondrial-mediated) pathway, involving BiD
cleavage, cytochrome c release and disruption of mitochon-
drial membrane potential (34, 35). To understand cross talk
between mitochondrion- and death receptor-mediated cyto-
toxic pathways activated by Stx1, CHOP or DR5 expression in
differentiated THP-1 cells was silenced, and after siRNA trans-
fection, the relative loss of mitochondrial membrane potential
(	
m) following Stx1 treatment for 24 h was detected using
the JC-1 dye, which accumulates in the mitochondria and is
released into the cytoplasm with the loss of mitochondrial
membrane potential. As shown in Fig. 7, a partial reduction in
	
m following intoxication was observed in CHOP and DR5
knockdown cells (14%  0.01% and 16%  4.6%, respec-
tively) compared to treatment with Stx1 alone (37.3% 
4.7%). 	
m was not affected by Stx1A
 holotoxin or Stx1
B-subunit treatment.
Differential rates of Stx1-induced calpain cleavage correlate
with different rates of Stx1-induced apoptosis in monocytic
versus macrophage-like THP-1 cells. It is tempting to specu-
late that siRNA-mediated DR5 and CHOP gene silencing re-
veals apoptosis-inducing pathways selectively operative in un-
differentiated THP-1 cells, which would account for the failure
of DR5 and CHOP knockdown to reduce caspase-3 and -8
activation (Fig. 6C). Furthermore, our finding that apoptosis is
rapidly induced in monocytic THP-1 cells suggests that Stx1
may activate apoptotic mechanisms prior to upregulated
TRAIL and DR5 expression. Calcium-dependent death signal-
ing via proteolysis of calpain has been well characterized as an
alternative pathway to activate caspases (2, 65). We reported
that the ER stress response induced by Stx1 in monocytic
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THP-1 cells triggered the rapid release of Ca2 from intracel-
lular stores and the rapid activation of calpain, with calpain
cleavage products evident within 1 h of Stx1 treatment (36). To
examine whether a similar phenomenon occurs in macro-
phage-like THP-1 cells, cells were left untreated or treated
with Stx1 for various times, cellular lysates were prepared, and
calpain cleavage was detected by immunoblotting. Stx1 acti-
vated calpain cleavage in macrophage-like THP-1 cells, but
with kinetics very different from those in monocytic cells. Cal-
pain cleavage was first detected beginning 4 h after toxin treat-
ment and progressively increased throughout the duration of
the experiment (Fig. 8A, left panel). It is noteworthy that we
failed to detect calpain proteolysis in macrophage-like cells
treated with Stx1A for 12 h (Fig. 8A, right panel). In terms of
kinetics and band intensities, Stx1-induced calpain cleavage
was markedly faster and higher in undifferentiated monocytic
cells than in toxin-treated differentiated macrophage-like cells
(Fig. 8B). Thus, the early activation of calpain and caspases
may contribute to the rapid-apoptosis phenotype of Stx1-
treated monocytic THP-1 cells.
DISCUSSION
Apoptosis is programmed cell death which is initiated by
intracellular signaling pathways. Apoptosis is essential for nor-
mal development, tissue/organ homeostasis, and removal of
damaged cells. It has become clear that a number of bacterial
pathogens have evolved mechanisms to manipulate the host
apoptosis response, presumably to the benefit of the pathogen
(10, 15). Apoptotic signaling can be categorized into two path-
ways, the intrinsic and extrinsic pathways. The intrinsic path-
way is initiated in response to cellular stress, such as DNA
damage, hypoxia, or the presence of misfolded proteins within
the ER. The intrinsic pathway is activated through changes in
FIG. 6. Caspase activation following Stx1 treatment of DR5 or CHOP siRNA-transfected macrophage-like and monocytic THP-1 cells.
(A) Differentiated THP-1 cells were treated with Stx1, Stx1A, or Stx1 B subunits for 8 h. Cells were lysed, followed by Western blotting with
anti-caspase-3 and -8 antibodies. Membranes were then stripped and reprobed with antiactin antibody for an equal-protein-loading control.
(B) Differentiated THP-1 cells (D-THP1) were transfected with siRNAs specific for DR5 (siDR5), CHOP (siCHOP), or nontargeting siRNA
(NTsiRNA) or were mock transfected (Mock) with reagent only for 72 h. After washing, cells were incubated with or without Stx1 for 8 h. Cell
lysates were analyzed for caspase-3 and -8 cleavage as described above. A representative Western blot is shown in the left panel; the bar graph
(right panel) depicts results from at least three independent experiments with caspase activation expressed as fold increase compared to control
(untreated) cells. (C) Undifferentiated THP-1 cells (UD-THP1) were transfected with siRNAs and treated with Stx1 as outlined above. A
representative Western blot showing caspase-3 and -8 cleavage is shown.
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mitochondria that affect membrane permeability and potential.
The extrinsic pathway is activated through engagement of
death domain-containing receptors of the TNF receptor super-
family, TNFR1, Fas, and the TRAIL receptors, with their
cognate apoptosis-inducing ligands, TNF-, FasL, and TRAIL,
respectively (11, 27). We have previously shown that the treat-
ment of monocytic and macrophage-like THP-1 cells with Stx1
activates signaling cascades which may contribute to initiation
of both intrinsic and extrinsic pathways of apoptosis induction,
including signaling through the ER stress response, the rapid
activation of caspase-8 and BID, the release of intracellular
Ca2 from ER, stores and activation of calpains (22, 35, 36).
We show here that Stx1 treatment of monocytic and macro-
phage-like THP-1 cells resulted in increased expression of
TRAIL and DR5. TRAIL is a type II transmembrane protein
originally cloned based on its sequence homology to TNF-
and FasL (45, 66). Like other members of the TNF superfam-
ily, TRAIL may be cleaved by metalloproteases to form bio-
active soluble TRAIL (41). Similar to other members of the
FIG. 7. CHOP and DR5 signaling activates the mitochondrion-
mediated pathway of apoptosis in Stx1-treated macrophage-like
THP-1 cells. Differentiated THP-1 cells were transfected with siRNAs
specific for DR5 (siDR5), CHOP (siCHOP), or nontargeting siRNA
(NTsiRNA) or were mock transfected (Mock) with reagent only for
72 h and then treated without or with Stx1, Stx1A, or Stx1 B subunits
for 24 h. After incubation, JC-1 was used to measure 	
m (loss of
mitochondrial membrane potential) by flow cytometry. Control cells
were maintained in medium for 24 h. The percent 	
m was compared
to that for control (untreated) cells. The data are the means  SEM
from three independent experiments.
FIG. 8. Stx1 treatment of macrophage-like THP-1 cells triggers the delayed activation of calpain, which requires toxin enzymatic activity.
(A) Differentiated macrophage-like THP-1 cells were incubated without or with Stx1 for 0 to 24 h (left panel), or with Stx1 or Stx1A for 12 h
(right panel). Cell lysates were prepared and subjected to SDS-PAGE. Calpain cleavage was detected by Western blotting with calpain-specific
antibodies. (B) Undifferentiated (U) and differentiated (D) THP-1 cells were incubated with Stx1 for various times. At the indicated time points,
cell lysates were prepared and subjected to Western blotting to assess calpain cleavage as described for panel A. C, control (untreated) cells.
Representative gels from at least three independent experiments are shown. The bar graph (below in panel B) depicts results from at least three
independent experiments with calpain activation (cleavage) as fold increase compared to control values (untreated cells).
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TNF superfamily, TRAIL forms homotrimers and therefore
induces the trimerization of its membrane receptors. Five
TRAIL receptors have been characterized, i.e., DR4, DR5,
DcR1, DcR2, and osteoprotegerin (OPG). In humans, only
DR4 and DR5 possess intact death domains, while DcR1 and
DcR2 are considered “decoy” receptors lacking functional
death domains, and TRAIL binds OPG with lower affinity than
it does DR4 and DR5. When DR4 or DR5 binds TRAIL,
trimerization recruits the adaptor protein FADD, as well as
procaspase-8 or procaspase-10, to the receptor-ligand com-
plex. Following autoproteolysis to generate functional
caspase-8, caspase-3, -6, and -7 may be directly activated, or
BID may be cleaved to activate apoptotic signaling cascades
through mitochondrial membrane perturbation.
The RT-PCR analyses presented here suggest that DR5
expression is positively regulated by Stx1, at least in part, at the
transcriptional level. Apoptotic signaling through TRAIL-DR5
ligation is functional in monocytic and macrophage-like THP-1
cells, as evidenced by the increased percentages of apoptotic
cells detected when exogenous sTRAIL was added to intoxi-
cated cells. Anti-TRAIL antibody treatment protected cells
from cytotoxicity mediated by Stx1. Toxin enzymatic activity
was required for increased TRAIL and DR5 expression. How-
ever, the protein synthesis inhibitor cycloheximide, which does
not undergo retrograde transport to the ER or undergo retro-
translocation across the ER membrane, failed to induce apop-
tosis or increased DR5 expression. TRAIL binding to the
death domain-containing receptor DR5 results in receptor tri-
merization and recruitment of the DISC, which contains pro-
caspase-8. Within this macromolecular scaffold, procaspase-8
is thought to be activated by proximity-dependent autoproteo-
lysis (19). Caspase-8 may then directly cleave procaspase-3 or,
alternatively, may cleave the BH3-only Bcl2 family member
BID. In its truncated form, tBID intercalates within the mito-
chondrial membrane, where it may facilitate pore formation by
the proapoptotic Bcl2 family members Bax and Bak, leading to
increased mitochondrial membrane permeability, release of
cytochrome c, formation of the apoptosome, activation of
caspase-9 and -3, and apoptosis (11, 27). We have previously
shown that these downstream events follow treatment of
monocytic and macrophage-like THP-1 cells with Stx1 (22, 35,
36), suggesting that TRAIL-DR5 ligation occurs and facilitates
apoptosis induction in these cells. Furthermore, TRAIL and
DR5 seem to be uniquely involved in Stx1-induced apoptosis in
THP-1 cells, as we have shown that other members of the
tumor necrosis factor and tumor necrosis factor receptor su-
perfamilies, TNF/TNFR1 and FasL (Apo)/Fas, are not in-
volved in apoptotic signaling in THP-1 cells (34, 35).
The precise mechanism by which Stx1 regulates TRAIL and
DR5 expression remains to be characterized, although the
signaling proteins TRAF-2 and RIP are known to associate
with the TRAIL-DR5 DISC. Signaling through TRAF-2 and
RIP activates the transcriptional factor NF-B (52). We have
previously shown that Stx1 activates NF-B signaling in mac-
rophage-like THP-1 cells, and TRAIL and DR5 gene expres-
sion is regulated by NF-B (20, 48, 54, 64). DR5 expression is
also regulated by CHOP (68), and Stx1 treatment of monocytic
and macrophage-like THP-1 cells increases CHOP expression
(33, 36). Furthermore, we show here that RNAi knockdown of
CHOP and DR5 expression partially protects macrophage-like
cells from the cytotoxic action of Stx1. Taken together, these
findings suggest that apoptosis induction by Stx1 may occur in
multiple stages involving both the intrinsic and extrinsic path-
ways. Functional toxins must be routed to the ER, processed,
and translocated into the cytoplasm. Retrograde transport and
toxin enzymatic activity then initiate the ER stress response,
leading to rapid caspase-8 activation and activation of NF-B
and CHOP signaling pathways. This initial response to Stx1
leads to increased TRAIL and DR5 expression, which, acting
in an autocrine or paracrine manner, may augment apoptotic
signaling initiated by the toxin. However, TRAIL-DR5 signal-
ing may be relatively more important in the delayed-apoptosis
phenotype of differentiated, macrophage-like THP-1 cells, as
inhibition of DR5 or CHOP expression with siRNAs did not
fully attenuate caspase activation or apoptosis in undifferenti-
ated, monocytic THP-1 cells. These data suggest that other
proapoptotic signaling cascades may contribute to rapid apop-
tosis induction. In this regard, the differential kinetics of cal-
pain activation leading to direct caspase activation may con-
tribute to the cell maturation-dependent differences in
apoptosis induction that we have observed using THP-1 cells
(Fig. 6). As shown in Fig. 8, calpain is rapidly cleaved in
Stx1-treated monocytic cells, while calpain activation is de-
layed in macrophage-like cells.
While we have focused on the elucidation of Stx1-induced
apoptotic signaling mechanisms, it is important to note that
only a fraction of differentiated THP-1 cells die following pro-
longed (72-h) exposure to Stx1 (22). The mechanism of cell
survival in the face of intoxication is not clear, but it is impor-
tant to note that following binding to DR4 or DR5, TRAIL has
been reported to activate both apoptotic and prosurvival sig-
naling in some cell types. Prosurvival signaling is mediated
through activation of NF-B, Akt (or protein kinase B), and
the mitogen-activated protein kinases (MAPKs) extracellular
signal-regulated kinase (ERK), Jun N-terminal protein kinase
(JNK), and p38 (7). We have shown that NF-B, Akt, and
MAPK pathways are activated by Stxs in macrophage-like
THP-1 cells (4, 16, 48), suggesting that survival of toxin chal-
lenge by some differentiated THP-1 cells, and the delayed
onset of apoptosis seen with other cells, may be related to the
activation of “balanced” survival versus apoptosis signaling
pathways in the macrophage-like cells, while signaling in the
monocytic cells primarily triggers apoptosis.
The human leukemia cell line THP-1 expresses Gb3 (47) and
contains a mutation in the gene encoding the tumor suppressor
p53 (58). Gb3-expressing tumors are frequently aggressive and
resistant to anticancer drugs, and p53-deficient cells frequently
develop resistance to chemotherapeutic agents. Thus, novel
treatment options for these malignant tumors are needed. The
capacity of Stx1 to induce apoptosis in Gb3
 p53 leukemia
cells highlights the potential for the toxins to be utilized as
anticancer agents. A single intratumor injection of Stx1 into
athymic nude mice bearing Gb3
 human malignant meningi-
oma xenografts improved survival. Survival was associated with
the marked increase of TUNEL cells within the graft (49). In
a screening of 25 breast cancer tissues for sensitivity to Stx1-
induced apoptosis, it was shown that sensitivity correlated with
Gb3 expression (28). Using immunohistochemical techniques,
only 17 of the 25 tissue samples expressed Gb3. However,
arterioles serving the tumors were rich in Gb3, suggesting that
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Shiga toxins may be used to disrupt the vascular networks
serving tumors. A major hurdle in the use of bacterial toxins in
cancer therapy is targeting of the cytotoxic effect to trans-
formed cells while sparing normal cells. Our observation that
Stx1 increases TRAIL and DR5 expression in a myelogenous
leukemia cell line is interesting in light of the fact that TRAIL
is reported to be selectively involved in apoptosis induction in
transformed cells, while most nontransformed cells are refrac-
tory to apoptosis induction by TRAIL (1, 27). Furthermore,
downregulation of expression of the antiapoptotic Bcl-2 family
member Bcl-2 (3, 59), the caspase-8 activation inhibitor c-FLIP
(24, 29), or the apoptosis inhibitor XIAP (9) has been shown to
sensitize transformed cells to the cytotoxic action of TRAIL.
Shiga toxins have been shown to be capable of downregulating
expression of Bcl-2 and IAPs (35, 36) in monocytic THP-1 cells
and of inducing rapid c-FLIP degradation in endothelial cells
(13). Thus, our observation that the addition of sTRAIL in-
creases apoptosis in the presence of Stx1 may be of potential
clinical relevance. Recombinant human TRAIL (rhTRAIL) is
currently undergoing clinical trials for efficacy in treatment of
tumors and hematological malignancies (67). A number of
chemotherapeutic agents, such as rituximab or paclitaxel, car-
boplatin, and bevacizumab combination therapy, have been
shown to increase the efficacy of rhTRAIL. The potential for
Shiga toxins to be employed as specific cytotoxic agents for
transformed cells will require a more thorough survey of mul-
tiple transformed cells types as well as screening of primary
cells for TRAIL and DR5 expression and apoptosis induction
following intoxication.
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